Could an Exercise Pill Pass Its First Human Safety Check? ENV-308
TL;DR Summary
Enveda’s ENV-308, a pill designed to mimic the exercise-linked molecule Lac-Phe, successfully completed a Phase I trial in 88 healthy volunteers, showing safety, tolerability, and an exceptional GI safety profile. Early signs suggest it may influence leptin levels and aid weight maintenance and muscle preservation, with Phase II planned for weight-loss maintenance and exploration in migraines and inflammatory bowel disease. It’s not a substitute for real exercise, but could offer a convenient metabolic aid as development continues.
- An ‘Exercise Pill’ Just Cleared Its First Human Test Gizmodo
- A pill that mimics exercise? Early results on drug designed to maintain both weight loss and muscle mass STAT
- Enveda Reports Positive Phase 1 Results for ENV-308, the First Pill Designed From the Chemistry of Exercise Business Wire
- Enveda to move AI-discovered drug into mid-stage study for weight-loss maintenance FirstWord Pharma
- Enveda’s exercise-simulating obesity tablet clears early clinical test BioSpace
Reading Insights
Total Reads
0
Unique Readers
9
Time Saved
3 min
vs 4 min read
Condensed
88%
649 → 77 words
Want the full story? Read the original article
Read on Gizmodo